English Archives

How to bring bacterial risk control strategies within financial reach

by jaycornell | May 5, 2025

Kathleen Rowe Sr. Global Health Policy Director Cerus BV

Strategies to minimise budget impact and increase cost effectiveness of pathogen inactivation

by jaycornell | May 5, 2025

Filip De Groof Consultant Cerus BV

Pathogen reduction of double dose platelet concentrates from pools of eight Buffy coats: product quality, safety and economic aspects

by jaycornell | May 5, 2025

Dr. Konrad Rosskopf Dept. Transfusion Medicine University Hospital of Graz, Austria

Economic aspects of introducing pathogen inactivated platelets in treatment cycle of oncology patients in Germany

by jaycornell | May 5, 2025

Prof. Dr. Florian Kron Managing Director VITIS Healthcare group

Transfusing the right product to the right patient

by jaycornell | May 5, 2025

Dr. Fabrice Cognasse, PhD Auvergne-Rhône-Alpes Regional Blood Center of the French National Blood Establishment INSERM 1059/University of Lyon Saint-Etienne, France